Evidence map›Paper›PMID 38129524›Full record

ArticleScientific reports2023

Rapid and accurate detection of SARS-CoV-2 using the RHAM technology.

Zhuo Xiao, Xiaoli Liu, Xiaolong Kang, Yaoheng Feng, Lijun Zheng, Chong Chen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhuo XiaoGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China.
Xiaoli LiuGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China.
Xiaolong KangGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China.
Yaoheng FengGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China.
Lijun ZhengGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China.
Chong ChenGuangzhou Pluslife Biotech Co., Ltd., No. 6 Lianhuayan Road, Huangpu District, Guangzhou, 510700, Guangdong, China. noah.chen@pluslife.com.
421 Hospital of PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid and sensitive detection of pathogens is of utmost importance in interrupting the transmission chain of infectious diseases. In recent years, this has proven to be vital during the coronavirus disease (COVID-19) global pandemic that put countless lives at risk. Numerous molecular diagnostic methods were used, including RT-PCR, NASBA, E-SDA, E-RCA, LAMP, and RPA. However, these technologies potentially require primer optimization and complex instruments. Here, we propose the RHAM (RNase Hybridization-Assisted amplification) system as a rapid, specific, and sensitive molecular diagnosis platform. Combining the LAMP and RNase HII-mediated fluorescent reporter, the RHAM system can amplify and visualize the target in one isothermal system with high sensitivity (5 × 10

Indexed as

COVID-19SARS-CoV-2HumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesRNA, ViralSensitivity and SpecificityRNA, Viral

Identifiers

PMID38129524
PMCPMC10739982
OpenAlexW4390054320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.